Core Viewpoint - Weikang Pharmaceutical (300878.SZ) announced the initiation of a Phase III clinical trial to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis [1] Group 1: Clinical Trial Details - The clinical trial is a randomized, double-blind, multi-center, placebo-controlled study [1] - The trial is focused on patients with liver fibrosis due to chronic hepatitis B, specifically those with liver qi deficiency and blood stasis syndrome [1] - The project is led by Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, along with 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing Medical University First Affiliated Hospital [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-038 2、注册分类：中药 1.1 类 3、剂型：颗粒剂 关于黄甲软肝颗粒启动临床三期试验的公告 4、适应症：慢性乙型病毒性肝炎肝纤维化（肝郁脾虚兼瘀血阻络证） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 5、临床试验分期：Ⅲ期临床试验 2025 年 9 月 25 日，浙江维康药业股份有限公司(以下简称"公司")与盈科 瑞（珠海金湾）制药有限公司共同申办，牵头单位为上海中医药大学附属曙光医 院和参研的安徽医科大学第一附属医院、重庆大学附属三峡医院、重庆医科大学 附属第一医院等 19 家临床试验中心组织召开了关于开展"评价黄甲软肝颗粒治 疗慢性乙型病毒性肝炎肝纤维化（肝郁脾虚兼瘀血阻络证）的有效性和安全性的 随机、双盲、多中心、安慰剂对照的Ⅲ期临床试验"的项目启动会。现将主要相 关情况公告如下： 6、试验负责单位：上海中医药大学附属曙光医院 一、药品基本信息 浙江维康药业股份有限公司 1、药品名称：黄甲软肝颗粒 五、风险提示 本次Ⅲ期临床试验的启动将进一步推进黄甲软肝颗粒的上市进程。上述事项 属 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

证券之星消息，9月24日中药板块较上一交易日下跌0.28%，维康药业领跌。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | 4.27% | 21.58万 | | 1.41亿 | | 600129 | 太极集团 | 21.75 | 3.97% | 16.50万 | | 3.54Z | | 603998 | 方盛制药 | 11.83 | 3.23% | 44.30万 | | 5.23亿 | | 300181 | 佐力药业 | 18.09 | 3.02% | 17.62万 | | 3.17亿 | | 000423 | 东阿阿胶 | 48.10 | 2.69% | 10.18万 | | 4.87亿 | | 600329 | 达仁堂 | 45.08 | 2.69% | 7.64万 | | 3.43亿 | | 300534 | ...

Core Insights - The latest financing balance of the ChiNext market is 503.632 billion yuan, a decrease of 2.051 billion yuan compared to the previous period, with 37 stocks experiencing a financing balance increase of over 10% [1] - On September 19, the ChiNext index fell by 0.16%, with a total margin balance of 505.245 billion yuan, down by 2.063 billion yuan from the previous trading day [1] - Among the stocks with increased financing balances, the largest increase was seen in Weikang Pharmaceutical, which had a financing balance of 46.5396 million yuan, up by 35.67% [1][3] Financing Balance Increase - A total of 358 stocks in the ChiNext market saw an increase in financing balance, with 37 stocks increasing by more than 10% [1] - The stocks with significant financing balance increases include: - Weikang Pharmaceutical: 46.5396 million yuan, +35.67%, closing price 23.80 yuan, +6.06% [3] - Kailong High-Tech: 90.1017 million yuan, +34.63%, closing price 19.00 yuan, -7.27% [3] - Kalait: 176.0133 million yuan, +30.05%, closing price 71.84 yuan, +14.29% [3] - The average increase for stocks with over 10% financing balance growth was 2.11%, with notable performers including Kalait, Tongyu New Materials, and Suzhou Tianmai, which saw increases of 14.29%, 12.14%, and 11.55% respectively [1][3] Financing Balance Decrease - A total of 586 stocks experienced a decrease in financing balance, with 10 stocks seeing a decline of over 10% [4] - The stocks with the largest decreases in financing balance include: - Junting Hotel: 16.921 million yuan, -17.52%, closing price 26.47 yuan, +3.16% [4] - Wavelength Optoelectronics: 36.291 million yuan, -17.37%, closing price 108.30 yuan, +14.60% [4] - Fushite: 5.4887 million yuan, -16.62%, closing price 32.72 yuan, -3.71% [4] Fund Flow - On September 19, among the stocks with increased financing balances, 25 stocks saw net inflows of main funds, with the highest inflows in Kunlun Wanwei, Capital Online, and Sanhuan Group, amounting to 573 million yuan, 182 million yuan, and 123 million yuan respectively [2] - Conversely, 12 stocks experienced net outflows, with the largest outflows in Lihexing, Suao Sensor, and Sudawige, totaling 178 million yuan, 75.5 million yuan, and 46.1427 million yuan respectively [2]

证券之星消息，9月18日中药板块较上一交易日下跌0.74%，维康药业领跌。当日上证指数报收于 3831.66，下跌1.15%。深证成指报收于13075.66，下跌1.06%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日中药板块主力资金净流出4.56亿元，游资资金净流入1.93亿元，散户资金净流入 2.63亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300158 振东制药 | | 7468.12万 | 12.28% | 307.26万 | 0.51% | -7775.39万 | -12.79% | | 002317 | 众生药业 | 4981.74万 | 5.33% | -3446.28万 | -3.68% | -1535.47万 | -1.64% | ...

9月17日，维康药业（维权）盘中下跌2.02%，截至10:30，报23.32元/股，成交6744.97万元，换手率 1.97%，总市值33.77亿元。 资料显示，浙江维康药业股份有限公司位于浙江省丽水经济开发区遂松路2号，成立日期2000年3月31 日，上市日期2020年8月24日，公司主营业务涉及现代中药及西药的研发、生产和销售。主营业务收入 构成为：中西成药97.16%，其他(补充)2.84%。 维康药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：肝炎治疗、抗流感、医药电 商、中药、小盘等。 截至6月30日，维康药业股东户数9892.00，较上期减少12.06%；人均流通股14569股，较上期增加 13.71%。2025年1月-6月，维康药业实现营业收入1.15亿元，同比减少61.42%；归母净利润-6421.97万 元，同比减少552.50%。 分红方面，维康药业A股上市后累计派现1.79亿元。近三年，累计派现5540.00万元。 责任编辑：小浪快报 资金流向方面，主力资金净流出289.42万元，大单买入795.25万元，占比11.79%，卖出1084.67万元，占 比16.08%。 维 ...

Market Overview - On September 16, the Chinese medicine sector rose by 0.04% compared to the previous trading day, with Weikang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers in Chinese Medicine Sector - Weikang Pharmaceutical (300878) closed at 23.80, with an increase of 8.23% and a trading volume of 86,600 shares, amounting to a transaction value of 201 million yuan [1] - Renhe Pharmaceutical (000650) closed at 6.73, up 5.49%, with a trading volume of 1.3482 million shares and a transaction value of 899 million yuan [1] - Panlong Pharmaceutical (002864) closed at 31.21, increasing by 3.52%, with a trading volume of 94,600 shares and a transaction value of 293 million yuan [1] Top Losers in Chinese Medicine Sector - ST Changyao (300391) closed at 4.00, down 1.72%, with a trading volume of 85,400 shares and a transaction value of 34.11 million yuan [2] - Kangyuan Pharmaceutical (600557) closed at 16.05, down 1.41%, with a trading volume of 117,500 shares and a transaction value of 189 million yuan [2] - Lingrui Pharmaceutical (600285) closed at 22.55, down 1.10%, with a trading volume of 89,100 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 690 million yuan from institutional investors, while retail investors saw a net inflow of 569 million yuan [2] - The top stocks with significant net inflows from retail investors include Shanghai Kaibao (300039) with a net inflow of 17.84 million yuan [3] - Guizhou Sanli (603439) also saw a net inflow of 17.76 million yuan from retail investors [3]

Core Viewpoint - The company confirmed that the funds and interest occupied by the actual controller have been fully returned, and it is actively developing innovative traditional Chinese medicine projects [2]. Group 1: Financial Integrity - The actual controller of the company has returned all occupied funds and interest [2]. - There is no indication of these transactions on the balance sheet, raising questions from investors [2]. Group 2: Product Development - The company is focusing on innovative traditional Chinese medicine products, including projects like Shen Dan Tong Nao Drop, Huang Jia Ruan Gan Granule, and new drugs such as Kai Xin San and Jin Shui Liu Jun Decoction [2]. - The company has provided detailed progress updates in its regular reports and will disclose any relevant matters as required [2].

Market Overview - On September 9, the traditional Chinese medicine sector declined by 0.87% compared to the previous trading day, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3807.29, down 0.51%, while the Shenzhen Component Index closed at 12510.6, down 1.23% [1] Stock Performance - Weikang Pharmaceutical (300878) closed at 20.49, down 5.05% with a trading volume of 41,700 shares and a turnover of 87.3962 million yuan [2] - Wanbangde (002082) fell by 4.10% to 9.82, with a trading volume of 300,500 shares and a turnover of 298 million yuan [2] - New Tian Pharmaceutical (002873) decreased by 3.80% to 11.39, with a trading volume of 125,900 shares and a turnover of 14.5 million yuan [2] - Other notable declines include Tianmu Pharmaceutical (600671) down 3.51%, Zhendong Pharmaceutical (300158) down 3.14%, and Jiuzhitang (000989) down 2.89% [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 604 million yuan from institutional investors, while retail investors saw a net inflow of 563 million yuan [4] - Notable net inflows from retail investors include Yiling Pharmaceutical (002603) with a net outflow of 63.9047 million yuan from institutional investors and a net inflow of 52.8464 million yuan from retail investors [4] - Other companies with significant capital movements include Ma Yinglong (600993) with a net inflow of 29.999 million yuan from institutional investors and a net outflow of 10.7281 million yuan from retail investors [4]